Stay updated on Pembrolizumab and Radiotherapy in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Radiotherapy in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Radiotherapy in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3; no visible changes to the study details or page layout.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision history updated for study documents: added revision v3.4.2 and removed v3.4.1.SummaryDifference0.1%

- Check39 days agoChange DetectedAdded document revision tag v3.4.1 and removed v3.4.0; these are metadata updates that do not affect the study details, eligibility criteria, or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedUI text updates include the addition of glossary toggle options (Show glossary / Hide glossary), capitalization changes to QC-related labels ('Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and a revision update from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedRevision: v3.3.4 appears at the bottom of the page, replacing v3.3.3, with no changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check89 days agoChange DetectedAdded a Locations section with California as a study location; removed the California Locations heading. Revision: v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Radiotherapy in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Radiotherapy in NSCLC Clinical Trial page.